DeLoia JA - Search Results

1

High-resolution methylation analysis of the BRCA1 promoter in ovarian tumors.

Wilcox CB, Baysal BE, Gallion HH, Strange MA, DeLoia JA. Wilcox CB, et al. Among authors: deloia ja. Cancer Genet Cytogenet. 2005 Jun;159(2):114-22. doi: 10.1016/j.cancergencyto.2004.12.017. Cancer Genet Cytogenet. 2005. PMID: 15899382

2

BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study.

Thrall M, Gallion HH, Kryscio R, Kapali M, Armstrong DK, DeLoia JA. Thrall M, et al. Among authors: deloia ja. Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:166-71. doi: 10.1111/j.1525-1438.2006.00504.x. Int J Gynecol Cancer. 2006. PMID: 16515585

3

Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer.

Wilcox CB, Feddes GO, Willett-Brozick JE, Hsu LC, DeLoia JA, Baysal BE. Wilcox CB, et al. Among authors: deloia ja. BMC Cancer. 2007 Dec 11;7:223. doi: 10.1186/1471-2407-7-223. BMC Cancer. 2007. PMID: 18070364 Free PMC article.

4

Analysis of CHEK2 gene for ovarian cancer susceptibility.

Baysal BE, DeLoia JA, Willett-Brozick JE, Goodman MT, Brady MF, Modugno F, Lynch HT, Conley YP, Watson P, Gallion HH. Baysal BE, et al. Among authors: deloia ja. Gynecol Oncol. 2004 Oct;95(1):62-9. doi: 10.1016/j.ygyno.2004.07.015. Gynecol Oncol. 2004. PMID: 15385111

5

Centrosome abnormalities in ovarian cancer.

Hsu LC, Kapali M, DeLoia JA, Gallion HH. Hsu LC, et al. Among authors: deloia ja. Int J Cancer. 2005 Feb 20;113(5):746-51. doi: 10.1002/ijc.20633. Int J Cancer. 2005. PMID: 15499629 Free article.

6

Expression and activity of taxane-metabolizing enzymes in ovarian tumors.

DeLoia JA, Zamboni WC, Jones JM, Strychor S, Kelley JL, Gallion HH. DeLoia JA, et al. Gynecol Oncol. 2008 Feb;108(2):355-60. doi: 10.1016/j.ygyno.2007.10.029. Epub 2007 Dec 11. Gynecol Oncol. 2008. PMID: 18063021

7

Relationship between ERCC1 polymorphisms, disease progression, and survival in the Gynecologic Oncology Group Phase III Trial of intraperitoneal versus intravenous cisplatin and paclitaxel for stage III epithelial ovarian cancer.

Krivak TC, Darcy KM, Tian C, Armstrong D, Baysal BE, Gallion H, Ambrosone CB, DeLoia JA; Gynecologic Oncology Group Phase III Trial. Krivak TC, et al. Among authors: deloia ja. J Clin Oncol. 2008 Jul 20;26(21):3598-606. doi: 10.1200/JCO.2008.16.1323. J Clin Oncol. 2008. PMID: 18640939 Free PMC article. Clinical Trial.

8

Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.

Thrall MM, DeLoia JA, Gallion H, Avril N. Thrall MM, et al. Among authors: deloia ja. Gynecol Oncol. 2007 Apr;105(1):17-22. doi: 10.1016/j.ygyno.2006.10.060. Epub 2007 Jan 10. Gynecol Oncol. 2007. PMID: 17208284

9

Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; a Gynecologic Oncology Group study.

Krivak TC, Darcy KM, Tian C, Bookman M, Gallion H, Ambrosone CB, Deloia JA. Krivak TC, et al. Among authors: deloia ja. Gynecol Oncol. 2011 Jul;122(1):121-6. doi: 10.1016/j.ygyno.2011.03.027. Epub 2011 Apr 14. Gynecol Oncol. 2011. PMID: 21496891

10

Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype.

Kolbe DL, DeLoia JA, Porter-Gill P, Strange M, Petrykowska HM, Guirguis A, Krivak TC, Brody LC, Elnitski L. Kolbe DL, et al. Among authors: deloia ja. PLoS One. 2012;7(3):e32941. doi: 10.1371/journal.pone.0032941. Epub 2012 Mar 5. PLoS One. 2012. PMID: 22403726 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

58 results

Search Page